On April 20, 2026 AlphaGen Therapeutics (AlphaGen), a biopharmaceutical company that focuses on developing next-generation targeted alpha radiotherapies, reported that it will present preclinical data on two advanced radiopharmaceutical programs at the 2026 Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper), is being held in San Diego, California, from April 17–22.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
[212Pb]Pb-AG1002 is a next-generation non-agonist SSTR2-targeting alpha radiopharmaceutical. In preclinical studies, the compound demonstrated high binding affinity and a superior tumor-to-kidney (T/K) ratio compared to agonist radioligands. It showed robust tumor growth inhibition and survival benefit across multiple models with a very favorable safety profile.
[212Pb]Pb-AG1206 is a novel FAP-targeted alpha radioligand based on a macrocyclic peptide scaffold with picomolar binding affinity. The compound has rapid tumor accumulation and renal clearance, giving rise to high T/K ratio. It showed strong anti-tumor activity in multiple preclinical tumor models. Consistent with preclinical observations, patient imaging IIT showed strong tumor uptake and clean tissue background.
"We have developed a robust pipeline of novel and differentiated targeted alpha radiotherapies. We are pleased to showcase our exciting progress in two such programs at AACR (Free AACR Whitepaper) Annual Meeting 2026." said Dr. Mai-Jing Liao, CEO of AlphaGen Therapeutics. "The data to be presented underscore our commitment to advancing next-generation targeted alpha therapies and delivering significant improvements for patients with difficult-to-treat tumors."
[212Pb]Pb-AG1002，SSTR2-targeted alpha therapy
Title: Preclinical evaluation of [212Pb]Pb-AG1002, a next generation SSTR2-targeting, non-agonist radiopharmaceutical
Poster Link: Abstract 5811: Preclinical evaluation of [212Pb]Pb-AG1002, a next generation SSTR2-targeting, non-agonist radiopharmaceutical | Cancer Research | American Association for Cancer Research (AACR) (Free AACR Whitepaper)
Session: Radiopharmaceutical Platforms for Theranostic Precision Oncology
Category: Experimental and Molecular Therapeutics
Date/Time: Tuesday, April 21, 2026, 2:00 PM – 5:00 PM PDT
Poster #: 5811
[212Pb]Pb-AG1206，FAP-targeted alpha therapy
Title: [212Pb]Pb-AG1206, A novel fibroblast activation protein-targeted radioligand therapy demonstrated excellent efficacy and safety profile
Poster Link: Abstract 5810: [212Pb]Pb-AG1206, A novel fibroblast activation protein-targeted radioligand therapy demonstrated excellent efficacy and safety profile | Cancer Research | American Association for Cancer Research (AACR) (Free AACR Whitepaper)
Session: Radiopharmaceutical Platforms for Theranostic Precision Oncology
Category: Experimental and Molecular Therapeutics
Date/Time: Tuesday, April 21, 2026, 2:00 PM – 5:00 PM PDT
Poster #: 5810
(Press release, AlphaGen Therapeutics, APR 20, 2026, View Source [SID1234664568])